Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | CES1 | P23141 | 2/20 | 0.37 |
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2884081 | 0.84 | SIRT6 (0.36) | MAPK1CES1FAAHKDM4EALDH1A1 | |
| SCHEMBL5268415 | 0.82 | SIRT6 (0.32) | FAAHKDM4E | |
| SCHEMBL1536342 | 0.82 | CA1 (0.44) | MAPK1KDM4EALDH1A1NPSR1CA1 | |
| SCHEMBL5212245 | 0.81 | SIRT6 (0.42) | MAPK1KDM4EALDH1A1CA1CA2 | |
| SCHEMBL2141020 | 0.78 | MAPK1 (0.43) | MAPK1CES1FAAHKDM4EALDH1A1 | |
| SCHEMBL23860306 | 0.77 | FAAH (0.40) | MAPK1CES1FAAHKDM4EALDH1A1 | |
| SCHEMBL5272991 | 0.76 | ERCC5 (0.40) | CES1FAAH | |
| SCHEMBL5268772 | 0.76 | FAAH (0.35) | CES1FAAH | |
| SCHEMBL5269847 | 0.75 | CLK1 (0.33) | — | |
| SCHEMBL27168903 | 0.73 | FAAH (0.40) | MAPK1CES1FAAHHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115819366-B | Preparation method of 2-aroyl substituted oxazole compound and compound prepared by same | 重庆医科大学 | 2024-05-24 | — | — | CN | disclosed |
| US-7598264-B2 | HIV integrase inhibitors | MERCK & CO., INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-20070254881-A1 | Pyrazole Derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-11-01 | — | — | US | disclosed |
| US-20070179196-A1 | Hiv integrase inhibitors | MERCK SHARP & DOHME CORP. | 2007-08-02 | — | — | US | disclosed |
| EP-1785418-A1 | PYRAZOLE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-05-16 | — | — | EP | disclosed |
| EP-1725556-A1 | HIV INTEGRASE INHIBITORS | Merck & Co., Inc. (US) | 2006-11-29 | — | — | EP | disclosed |
| WO-2005087768-A1 | HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 2005-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254881-A1 | Pyrazole Derivative | PTGER1, PTGS1, PTGER2 | MAPK1 107/4885CES1 1897/4885FAAH 1657/4885 |
| US-20070179196-A1 | Hiv integrase inhibitors | REV1, TYMP, POLR2H | MAPK1 855/4885CES1 1877/4885FAAH 3913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.